CorePharm Bio wins patent infringement trial against Astellas

Published: 2016-11-08 10:53:07

Updated: 2016-11-08 10:53:07

CorePharm Bio won the prohibition trial for patent infringement against Astellas Pharma.

CorePharm Bio(CEO Jung-Tae Kim) announced the 13 Civil Case Division of Seoul Central District Court ruled CorePharm Bio’s A-Care Tab(solifenacin fumarate) does not infringe the substance patent of the Astellas Pharm’s urinary dysfunction treatment, Vesicare Tab(solifenacin succinate), on the 3^rd of Novem...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.